Prognosis
Biopharma Giants Gather at JPMorgan Conference After ‘Depressing’ Year
- Some 48,000 expected in San Francisco at conference, sidelines
- Scores of smaller companies lacking cash seek investment
Medication displayed on shelves at a hospital in Lanarkshire, Scotland.
Photographer: Andy Buchanan/WPA Pool/Getty Images
This article is for subscribers only.
In the past three years, biotech companies have enjoyed a raft of successes, including rapidly developing vaccines for Covid-19, discovering a drug that can slow the progress of Alzheimer’s disease and securing approvals for one-time gene therapies for hard-to-treat conditions.
But none of that insulated the industry from the drubbing it received from Wall Street last year.